HIMS climbs over 4% after investors eye earnings release and legal updates

Traders Union
All News
Stocks
Hims & hers health rises 4.16% today

Highlights

Hims & Hers Health projects third quarter 2026 revenue of $892.88 million and earnings per share of $0.06.
The company faces multiple securities class action lawsuits, with an investor deadline set for November 2, 2026.
Shares of Hims & Hers Health trade below major moving averages with downside pressure, showing high likelihood of a move to $22.95 to $28.76 in the next five days.

Earnings optimism challenged by class action lawsuits and past growth

Hims & Hers Health Inc. is set to release third quarter 2026 earnings after the market closes on November 9, 2026, with estimates pointing to revenue of about $892.88 million and earnings per share of $0.06. The company is subject to several securities class action lawsuits, with an investor filing deadline on November 2, 2026. Earlier, the digital healthcare platform reported second-quarter revenue growth.

Anton Kharitonov, expert at Traders Union, sees Hims & Hers Health under ongoing downside pressure. He notes the technical setup remains unfavorable with price below major moving averages and negative momentum indicators. The unresolved legal risks and looming investor deadlines cast further doubt over near-term upside. He is critical of the transient rebound, describing it as fragile within a volatile range. "Until HIMS clears legal clouds and breaks above $27 with volume, I remain defensive on the stock's prospects," Kharitonov states.

Viktoras Karapetjanc, expert at Traders Union, focuses on the revenue growth and market anticipation of upcoming earnings. He points to constructive sentiment as investors position for fresh results, even against a backdrop of legal challenges. The analyst sees opportunity for HIMS to surprise, with robust fundamentals supporting interest. "With strong revenue estimates and heightened interest, I believe the market offers attractive setups for optimistic buyers," Karapetjanc says.

Sholanke Dele, market strategist, remains cautious on HIMS due to legal headwinds and the stock's technical weakness. He highlights negative momentum and high volatility as warning signs for traders. News of class actions reinforces risk, dampening short-term sentiment. "Elevated volatility and legal uncertainty mean now is not the time for aggressive positioning in HIMS," Dele warns.

Bearish momentum persists as indicators signal weak rebound potential

Hims & Hers Health is trading below its 20-day, 50-day, and 200-day moving averages, set at $28.72, $28.87, and $27, respectively, which indicates sustained downside pressure across all timeframes. The near-term ceiling is defined by the 200-day moving average at $27, while key support is at $25.19, corresponding to the day's low. Additional resistance appears at the Ichimoku Kijun level of $28.44. Momentum signals remain negative: the MACD suggests ongoing sell pressure, and the Average Directional Index reads as neutral, highlighting weak trend strength. The Relative Strength Index is neutral, but both the Stochastic RSI and Commodity Channel Index are in the oversold zone, reflecting potential for a rebound. Bull/Bear Power shows a moderate advantage for buyers intraday, while the Awesome Oscillator remains negative, reinforcing bearish momentum. Price is consolidating near mid-range between $25.19 and $28.46, with volatility elevated at 12.98%. Early gains have cooled, giving way to more balanced trading through the session.

Earlier, analysts noted that Hims & Hers Health was experiencing sustained downside pressure driven by negative technical momentum and persistent legal concerns. The current setup reinforces this caution, with elevated volatility and ongoing legal risks highlighting $25.19 as the key level to monitor for potential breakdowns in the days ahead.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.